UniSuper Management Pty Ltd Purchases 6,545 Shares of Solventum Corporation $SOLV

UniSuper Management Pty Ltd grew its holdings in shares of Solventum Corporation (NYSE:SOLV) by 25.0% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 32,723 shares of the company’s stock after purchasing an additional 6,545 shares during the quarter. UniSuper Management Pty Ltd’s holdings in Solventum were worth $2,389,000 at the end of the most recent reporting period.

Several other large investors have also recently modified their holdings of the business. CYBER HORNET ETFs LLC purchased a new stake in shares of Solventum during the 2nd quarter valued at approximately $28,000. Barrett & Company Inc. raised its holdings in Solventum by 206.2% during the 2nd quarter. Barrett & Company Inc. now owns 398 shares of the company’s stock valued at $30,000 after acquiring an additional 268 shares during the period. IMG Wealth Management Inc. purchased a new stake in shares of Solventum during the second quarter worth $31,000. MUFG Securities EMEA plc bought a new position in shares of Solventum in the second quarter worth $31,000. Finally, State of Wyoming purchased a new position in shares of Solventum in the second quarter valued at $33,000.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on SOLV. KeyCorp raised Solventum from a “sector weight” rating to an “overweight” rating and set a $97.00 price objective on the stock in a report on Monday. BTIG Research raised shares of Solventum from a “neutral” rating to a “buy” rating and set a $100.00 price target on the stock in a report on Tuesday, December 2nd. Zacks Research cut shares of Solventum from a “strong-buy” rating to a “hold” rating in a research note on Monday, December 1st. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Solventum in a report on Thursday, October 30th. Finally, Wall Street Zen upgraded shares of Solventum from a “hold” rating to a “buy” rating in a research note on Saturday, December 13th. Seven research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Solventum has an average rating of “Hold” and an average price target of $90.83.

Solventum Trading Down 1.9%

Shares of SOLV opened at $77.51 on Wednesday. The firm’s 50 day simple moving average is $81.72 and its 200 day simple moving average is $75.77. The company has a market capitalization of $13.44 billion, a P/E ratio of 8.93, a P/E/G ratio of 7.23 and a beta of 0.34. The company has a debt-to-equity ratio of 1.03, a current ratio of 1.50 and a quick ratio of 1.14. Solventum Corporation has a 1-year low of $60.70 and a 1-year high of $88.20.

Solventum (NYSE:SOLV) last released its quarterly earnings results on Thursday, November 6th. The company reported $1.50 EPS for the quarter, topping analysts’ consensus estimates of $1.43 by $0.07. The business had revenue of $2.10 billion during the quarter, compared to analysts’ expectations of $2.05 billion. Solventum had a net margin of 18.13% and a return on equity of 28.01%. The business’s quarterly revenue was up .7% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.64 EPS. Solventum has set its FY 2025 guidance at 5.980-6.080 EPS. Sell-side analysts forecast that Solventum Corporation will post 6.58 earnings per share for the current fiscal year.

Solventum declared that its Board of Directors has authorized a share buyback plan on Thursday, November 20th that permits the company to buyback $1.00 billion in outstanding shares. This buyback authorization permits the company to repurchase up to 7.5% of its shares through open market purchases. Shares buyback plans are often an indication that the company’s management believes its stock is undervalued.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.